FDA advisers back approval of Bayer's PAH drug riociguat

An FDA advisory panel recommended the approval of Bayer's riociguat as a treatment for two types of pulmonary arterial hypertension. The agency is expected to issue its decision in October. If approved, the drug would be marketed as Adempas.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA